Issued on behalf of Aleen Inc.
VANCOUVER – USA News Group News Commentary – Healthcare data interoperability platforms are projected to expand from $7.35 billion in 2025 to $14.06 billion by 2029[1], while healthcare customer data platforms consolidate information from EHRs, claims systems, laboratory systems, and imaging modalities into unified patient profiles[2]. Integrated clinical intelligence networks processing real-world health data are reshaping diagnostic capabilities, operational efficiency, and treatment coordination across care settings, positioning, LifeMD, Inc. (NASDAQ: LFMD), Veracyte, Inc. (NASDAQ: VCYT), GE HealthCare (NASDAQ: GEHC), and OneMedNet Corporation (NASDAQ: ONMD) to capture expanding market opportunities. Alongside these developments in clinical and diagnostic sectors, Aleen Inc. (CSE: ALEN-U) continues to operate strictly as a non-medical digital wellness platform, providing users with insights into general well-being without performing any medical or diagnostic functions.
Healthcare providers partnering with technology companies are developing AI-powered hospital operations platforms that have increased capacity to accept transfer patients by 22% while decreasing emergency department length of stay by 41.2%[3], while digital health platforms enable continuous real-time monitoring of vital signs through wearable devices that support predictive analytics and AI-powered clinical decision-making[4]. The convergence of data exchange infrastructure with intelligent diagnostic systems creates favorable conditions for companies delivering scalable health information platforms and precision diagnostics before widespread institutional adoption accelerates market transformation.
Aleen Inc. (CSE: ALEN-U), a Canadian digital wellness company, has announced the development of a personal account system designed to redefine how individuals interact with their wellness data. The upcoming personal account will serve as an intuitive hub where users can seamlessly upload, manage, and visualize their non-medical well-being information.
“This is about giving people ownership of their wellness journey,” said Oleksandr Luzin, Director of Aleen Inc. “We’re creating a system that turns information into confidence — and privacy into empowerment.”
The company previously announced it was beginning early concept testing for smart wellness analytics, with research highlighting three recurring user expectations: clear visualization of personal wellness patterns, strong privacy safeguards and control over shared information, and simple, non-medical interpretation of structured inputs.
“Our current focus is on understanding how an analytical tool can responsibly support everyday well-being — while staying entirely outside the realm of diagnostic or medical functions,” said Anastasiia Kalashnik, PR Specialist of Aleen Inc. “We are laying the groundwork for a feature that inspires awareness and self-reflection, not prescribes actions.”
Based in Ontario, Aleen Inc. went public in June 2025 and has developed an AI platform designed to help users understand their inputs and wellness indicators. The company operates in a rapidly expanding market, with the global digital wellness sector currently valued at approximately $12.87 billion in 2025 and projected to grow to $45.65 billion by 2034, representing annual growth of 15.1%. With about 57% of consumers now using digital apps and wearable devices to monitor their well-being, Aleen Inc. is positioned to capture a portion of this expanding demand.
The Aleen AI system can be accessed in two ways. Users can visit the Aleen website for free wellness insights, which helps raise awareness and encourages active engagement with personal well-being. Businesses can integrate Aleen Inc.’s technology via its API, allowing wellness apps and digital platforms to embed the AI-powered insights into their own services. The company generates revenue through its API offerings, available through a per-call option for businesses paying only for requests used, and a monthly subscription for consistent access.
Looking ahead to 2026, Aleen Inc. plans to launch the personal user accounts currently in development alongside the smart analytics features being tested. To fund these initiatives, Aleen Inc. is currently seeking between $20 million and $30 million in strategic investment, with plans to allocate 35% toward technology development, 30% toward sales and marketing efforts, and 20% for product expansion including mobile apps and specialized modules for corporate wellness programs.
With 12,643,300 common shares currently issued and outstanding, Aleen Inc. continues to build its presence in the digital wellness space under the leadership of CEO Inna Aksman. The company emphasizes that its platform is designed for preliminary wellness insights only and is not intended to replace consultations with healthcare professionals. Aleen Inc. does not provide medical diagnoses and is not regulated as a medical device by the FDA or other health authorities.
CONTINUED… Read this and more news for Aleen Inc. at:
LifeMD, Inc. (NASDAQ: LFMD) announced market-leading pricing for GLP-1 medications Wegovy and Ozempic, made possible through its ongoing collaboration with Novo Nordisk, offering the 0.25 mg and 0.5 mg doses at $199 per month for two fills for new patients—described as the lowest pricing available nationwide. The offering is available through the LifeMD Weight Management Program, which provides comprehensive support including virtual consultations with LifeMD’s dedicated clinical team, diagnostic testing, secure messaging through a personalized patient portal, and educational resources on diet and lifestyle changes for sustained weight loss and metabolic health.
“We are proud to continue offering the most competitive cash-pay pricing for GLP-1 throughout America,” said Justin Schreiber, Chairman and CEO of LifeMD. “Our goal remains the same: to maximize access to safe, FDA-approved medications through a frictionless virtual care experience that delivers long-term and sustainable weight loss and health benefits for our patients.”
This update follows recent national efforts to improve affordability and access to GLP-1 medications, including initiatives led by the White House and leading pharmaceutical manufacturers Novo Nordisk and Eli Lilly. LifeMD’s strategic shift from compounded GLP-1s to direct partnerships with leading pharmaceutical companies positions the company to meet rising demand for authentic obesity and metabolic medications while reinforcing its commitment to emerging regulatory standards and reimbursement frameworks through its scalable, integrated virtual care platform.
Veracyte, Inc. (NASDAQ: VCYT) has published landmark studies leveraging its Afirma GRID whole transcriptome-derived research platform to identify molecular classifiers that differentiate thyroid cancer risk groups prior to surgery. The studies, appearing in Frontiers in Endocrinology and Surgery, demonstrate how researchers can analyze molecular data from thyroid nodules to develop signatures providing enhanced prognostic information that may guide treatment decisions.
“We introduced Afirma GSC in 2017 to primarily help patients with indeterminate thyroid nodules—those that were not clearly benign or malignant—avoid unnecessary diagnostic surgery,” said Joshua Klopper, MD, Medical Director for Endocrinology of Veracyte. “Now, Veracyte is working to help clinical researchers better answer the next critical question for thyroid nodule care: ‘For those patients whose nodules are likely cancerous, how much surgery is needed?’ These studies, which evaluate biomarkers to determine a likely cancer’s aggressiveness, may one day enable us to answer this question.”
The Afirma GRID database contains sequencing of over 21,000 expressed genes for over 200,000 patients with thyroid nodules, enabling researchers to explore molecular markers that may guide patient treatment. The company’s commitment to making Afirma GRID available for research is rapidly fueling the expansion of thyroid cancer insights that could transform extent-of-surgery decision-making.
GE HealthCare (NASDAQ: GEHC) unveiled more than 40 technology innovations at RSNA 2025, including its new Photonova Spectra photon counting CT system and next-generation SIGNA MRI technology, backed by more than $3 billion in R&D investment since 2022. The company leads the industry with 100 FDA-authorized AI-enabled solutions designed to address critical challenges including staff shortages, rising imaging demand, and operational efficiency needs across care settings.
“As we shape the future of care, our commitment remains clear: to deliver transformative technologies that empower clinicians, drive efficiencies, and help improve patient outcomes across multiple care pathways,” said Peter Arduini, CEO of GE HealthCare. “We start by listening to our customers, and work backwards from their challenges, then develop truly differentiated products and solutions to meet their needs today and into the future.”
The company’s innovation renaissance spans smart devices and cloud-enabled AI solutions across multiple disease states, with recent strategic acquisitions including MIM Software for advanced imaging analytics, Spectronic Medical for radiation oncology planning, and icometrix to expand AI-enabled precision imaging capabilities. GE HealthCare commemorates 60 years of mammography innovation and 25 years of PET/CT leadership as it continues shaping the future of diagnostic imaging.
OneMedNet Corporation (NASDAQ: ONMD) announced industry-leading network expansion with clinical exams increasing 37% and patient records growing 38% in just three months since August 2025, cementing its position as one of the largest continuously refreshed, regulatory-grade Real-World Data networks globally. The company added approximately 380 provider sites bringing its total network to over 2,130 sites (+22%), expanded unique de-identified patient records by 13 million to exceed 47 million, and increased clinical exams and images by 50 million to exceed 186 million.
“Our subscription model is now gaining significant momentum,” said Aaron Green, President & CEO of OneMedNet. “In the $60 billion Real-World Evidence market, pharmaceutical, life-science, and AI customers subscribe to our platform for ongoing access to the precise, diverse, and longitudinal cohorts they require. Each incremental expansion of sites, encounters, and clinical exams materially enhances the depth, specificity, and value of those data feeds. The result is a powerful virtuous cycle: existing subscribers expand their commitments; new customers commit to long term partnerships and annual recurring revenue accelerates.”
The rapid multi-dimensional growth supports OneMedNet‘s subscription revenue strategy as pharmaceutical, life-science, and AI customers increasingly rely on the iRWD platform for ongoing access to precise, diverse, and longitudinal patient cohorts. The company’s network expansion positions it to capture growing market share as existing subscribers expand commitments and new customers pursue long-term partnerships.
Article Sources: https://usanewsgroup.com/2025/10/25/ai-engine-replaces-the-waiting-room-powering-the-660b-health-revolution/
CONTACT:
USA NEWS GROUP
(604) 265-2873
DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Aleen Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Aleen Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Aleen Inc. which were purchased in the open market. MIQ reserves the right to buy and sell, and will buy and sell shares of Aleen Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. Aleen’s solutions operate within the wellness domain and are not subject to FDA or Health Canada approval.
—
SOURCES:
- https://www.openpr.com/news/4277894/united-states-healthcare-data-interoperability-market
- https://www.globenewswire.com/news-release/2025/11/19/3191300/0/en/Global-Healthcare-Customer-Data-Platform-Market-Size-Share-Worth-USD-14-24-Billion-by-2034-at-a-32-10-CAGR-Custom-Market-Insights-Analysis-Outlook-Leaders-Report-Trends-Forecast-Se.html
- https://www.aha.org/aha-center-health-innovation-market-scan/2025-10-28-3-tech-partnerships-could-streamline-health-care
- https://www.marketsandmarkets.com/Market-Reports/digital-health-market-45458752.html
